| Year |
Citation |
Score |
| 2003 |
Maluf NK, Ali JA, Lohman TM. Kinetic mechanism for formation of the active, dimeric UvrD helicase-DNA complex. The Journal of Biological Chemistry. 278: 31930-40. PMID 12788954 DOI: 10.1074/Jbc.M304223200 |
0.646 |
|
| 2002 |
Lucius AL, Vindigni A, Gregorian R, Ali JA, Taylor AF, Smith GR, Lohman TM. DNA unwinding step-size of E. coli RecBCD helicase determined from single turnover chemical quenched-flow kinetic studies. Journal of Molecular Biology. 324: 409-28. PMID 12445778 DOI: 10.1016/S0022-2836(02)01067-7 |
0.705 |
|
| 1999 |
Ali JA, Maluf NK, Lohman TM. An oligomeric form of E. coli UvrD is required for optimal helicase activity. Journal of Molecular Biology. 293: 815-34. PMID 10543970 DOI: 10.1006/Jmbi.1999.3185 |
0.654 |
|
| 1997 |
Ali JA, Lohman TM. Kinetic measurement of the step size of DNA unwinding by Escherichia coli UvrD helicase. Science (New York, N.Y.). 275: 377-80. PMID 8994032 DOI: 10.1126/science.275.5298.377 |
0.836 |
|
| 1995 |
Ali JA, Orphanides G, Maxwell A. Nucleotide binding to the 43-kilodalton N-terminal fragment of the DNA gyrase B protein. Biochemistry. 34: 9801-9808. PMID 7626649 DOI: 10.1021/Bi00030A018 |
0.407 |
|
| 1993 |
Ali JA, Jackson AP, Howells AJ, Maxwell A. The 43-kilodalton N-terminal fragment of the DNA gyrase B protein hydrolyzes ATP and binds coumarin drugs. Biochemistry. 32: 2717-24. PMID 8383523 DOI: 10.1021/Bi00061A033 |
0.466 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2012 |
Liu T, Nair SJ, Lescarbeau A, Belani J, Peluso S, Conley J, Tillotson B, O'Hearn P, Smith S, Slocum K, West K, Helble J, Douglas M, Bahadoor A, Ali J, et al. Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors. Journal of Medicinal Chemistry. 55: 8859-78. PMID 23025805 DOI: 10.1021/Jm3011542 |
0.145 |
|
| 2024 |
Cottrell KM, Briggs KJ, Whittington DA, Jahic H, Ali JA, Davis CB, Gong S, Gotur D, Gu L, McCarren P, Tonini MR, Tsai A, Wilker EW, Yuan H, Zhang M, et al. Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with -Deleted Cancers. Journal of Medicinal Chemistry. PMID 38595098 DOI: 10.1021/acs.jmedchem.4c00133 |
0.12 |
|
| 2008 |
Manam RR, McArthur KA, Chao TH, Weiss J, Ali JA, Palombella VJ, Groll M, Lloyd GK, Palladino MA, Neuteboom ST, Macherla VR, Potts BC. Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides. Journal of Medicinal Chemistry. 51: 6711-24. PMID 18939815 DOI: 10.1021/jm800548b |
0.095 |
|
| 2006 |
Ge J, Normant E, Porter JR, Ali JA, Dembski MS, Gao Y, Georges AT, Grenier L, Pak RH, Patterson J, Sydor JR, Tibbitts TT, Tong JK, Adams J, Palombella VJ. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. Journal of Medicinal Chemistry. 49: 4606-15. PMID 16854066 DOI: 10.1021/Jm0603116 |
0.084 |
|
| 2004 |
Palombella VJ, Normant E, Ali J, Barrett J, Foley M, Gao Y, Ge J, Georges AT, Grayzel D, Grenier L, Hudak J, Pak R, Patterson J, Pien C, Pink M, et al. Anti-Tumor Activity of IPI-504, a Novel Hsp90 Inhibitor in Multiple Myeloma. Blood. 104: 4922-4922. DOI: 10.1182/Blood.V104.11.4922.4922 |
0.082 |
|
| 2006 |
Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, Pak RH, Ali JA, Dembski MS, Hudak J, Patterson J, Penders C, Pink M, Read MA, Sang J, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proceedings of the National Academy of Sciences of the United States of America. 103: 17408-13. PMID 17090671 DOI: 10.1073/Pnas.0608372103 |
0.069 |
|
| 2016 |
Kutok J, Ali J, Brophy E, Castro A, DiNitto J, Evans C, Faia K, Goldstein S, Kosmider N, Lescarbeau A, Liu T, Martin C, McGovern K, Nair S, Pink M, et al. Abstract B029: The potent and selective phosphoinositide-3-kinase-gamma inhibitor, IPI-549, inhibits tumor growth in murine syngeneic solid tumor models through alterations in the immune suppressive microenvironment Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-B029 |
0.063 |
|
| 2010 |
Tillotson B, Slocum K, Coco J, Whitebread N, Thomas B, West KA, MacDougall J, Ge J, Ali JA, Palombella VJ, Normant E, Adams J, Fritz CC. Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo. The Journal of Biological Chemistry. 285: 39835-43. PMID 20940293 DOI: 10.1074/Jbc.M110.141580 |
0.056 |
|
| 2015 |
McGovern K, Ali J, Brophy E, Castro A, DiNitto J, Evans C, Faia K, Goldstein S, Kosmider N, Lescarbeau A, Liu T, Martin C, Nair S, Pink M, Proctor J, et al. Abstract A192: The potent and selective phosphoinositide-3-kinase-γ inhibitor, IPI-549, inhibits tumor growth in murine syngeneic solid tumor models through alterations in the immune suppressive microenvironment Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A192 |
0.054 |
|
| 2013 |
Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE, Pink MM, Proctor JL, Lussier J, Martin CM, Hoyt JG, Tillotson B, Murphy EL, Lim AR, Thomas BD, et al. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chemistry & Biology. 20: 1364-74. PMID 24211136 DOI: 10.1016/J.Chembiol.2013.09.017 |
0.04 |
|
| 2014 |
O'Connell BC, O'Callaghan K, Tillotson B, Douglas M, Hafeez N, West KA, Stern H, Ali JA, Changelian P, Fritz CC, Palombella VJ, McGovern K, Kutok JL. HSP90 inhibition enhances antimitotic drug-induced mitotic arrest and cell death in preclinical models of non-small cell lung cancer. Plos One. 9: e115228. PMID 25542032 DOI: 10.1371/journal.pone.0115228 |
0.034 |
|
| 2016 |
Evans CA, Liu T, Lescarbeau A, Nair SJ, Grenier L, Pradeilles JA, Glenadel Q, Tibbitts T, Rowley AM, DiNitto JP, Brophy EE, O'Hearn EL, Ali JA, Winkler DG, Goldstein SI, et al. Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate. Acs Medicinal Chemistry Letters. 7: 862-7. PMID 27660692 DOI: 10.1021/Acsmedchemlett.6B00238 |
0.027 |
|
| Hide low-probability matches. |